echocardiography of cardiac amyloidosis frederick l. ruberg, md boston university medical center may...
TRANSCRIPT
Echocardiography of Cardiac Amyloidosis
Frederick L. Ruberg, MDBoston University Medical
CenterMay 25, 2005
What is amyloid
• Any misfolded protein that aggregates as a -sheet stains with Congo Red (birefringence)
• Implication in pathogensis of alzheimers disease ( amyloid)
• Systemic amyloidoses
The Systemic Amyloidoses
• Primary (AL) or light chain disease Plasma cell dyscrasia (clonal proliferation)
12-15% patients with myeloma have AL
Immunoglobulin light chains 12 month survival without treatment 6 month survival with cardiac disease Incidence is 1 in 100,000 in Western countries
• Familial (AF) Mutations in transthyretin (TTR) Ile 122 of particular interest
The Systemic Amyloidoses
• Senile systemic amyloid (SSA) TTR-based non-genetic (ie, TTR normal) Cardiac predilection Male gender, onset after age 60
• Secondary amyloidosis (AA) Chronic inflammatory states
• Other specific protein abnormalities apolipoprotein A-I and A-II, lysozyme
Merlini, G. et al. N Engl J Med 2003;349:583-596
Manifestations of AL
Falk, R. H. et al. N Engl J Med 1997
Diagnosis of Amyloidosis
Amyloid Cardiomyopathy
• Very poor prognosis (6 mo survival)• Restrictive cardiomyopathy with profound
abnormalities of diastolic function Systolic dysfunction late manifestation
• Classic teaching biventricular thickening in a small ventricle valvular thickening, “speckled pattern” Atrial enlargement Pericardial effusion/evidence of elevated filling
pressures
Echo Features
Rehman, JACC 2004
Amyloid Cardiomyopathy
• Patients do NOT respond to normal medication for CHF ACE inhibitors, beta-blockers, dig
• There is a treatment for AL amyloid Autologous bone marrow transplant
• Patient selection critical assessment of cardiac involvement
Advanced Amyloid
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
Continuum of Amyloid
• Advanced disease is too late• Initial changes are abnormalities of
diastolic function• As wall thickness progresses
restrictive physiology ensues Loss of limb lead voltage on ECG
• Systolic dysfunction late stage
Diastolic dysfunction
• Transmitral inflow E and A wave pattern E wave deceleration time IVRT
• Tissue Doppler mitral annular velocities E prime < 6 cm/s
• LA enlargement, IVC dilation• Restrictive physiology a late manifestation
Early Cardiac Amyloid
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
Early Cardiac Amyloid
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
After cardiac arrest
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
Hypertension vs. Amyloid
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
HTN vs Amyloid Doppler
HTN vs. Amyloid TDI
Moderate disease
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
Restrictive inflow, Absent A
Atrial arrest
• Absent A wave in setting of NSR• Restrictive pattern• Atrial amyloid infiltration and/or
markedly elevated LV DP• Risk of stroke/TIA, anticoagulation• Recovery of A wave following
successful BMT correlating to symptomatic improvement
Depressed E prime
Low stroke volume
Evidence of congestion
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
Advanced Amyloid
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
Restrictive filling
Treatment of AL
• Autonomic dysfunction, low stroke volumes Dependent on HR
• Beta blockers, ACEI poorly tolerated• Digoxin may bind to amyloid and promote
toxicity• Can use diuretics
Loop diuretics Aldactone/eplerenone
• Amiodarone• Proamatine (Midodrine) for BP support
Restrictive?
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
Grade I Dysfunction
LVOT obstruction
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
LVOT Obstruction
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
SSA (Senile Cardiac)
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
SSA Doppler
SSA Clinical Features
• Onset age greater than 60 years• Often exclusively cardiomyopathy• More benign clinical course than AL
Often tolerate medications that AL patients won’t
• TTR amyloid, must exclude AL as well as known mutations in TTR to diagnose
Familial TTR
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
Familial Amyloid CMP
• Over 80 mutations identified• Ile 122 in African Americans
2-4% heterozygotic allele frequency Unclear penetrance
Unclear importance in setting of HTN Onset of CMP after age 60 years
• Stabilization of TTR tetramer to stop amyloidogensis by diflunisal
Other agents in development
• Liver transplant/heart transplant
Stem Cell Transplant
• AL can respond to chemotherapy High dose melphalan with autologous
stem cell transplantation 8-year follow-up data (Skinner, et al. Ann Int Med 2004)
Median survival 1.6 yrs Exclusion EF < 40% or decompensated
CHF• Lower dose, marrow sparing regimens• Oral therapy, investigative drug
regimens
Survival after HDM/SCT
Skinner, et al. Ann Int Med 2004
Post-BMT changes?
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
Post BMT
• Symptomatic improvement without obvious change in echo appearance Hemodynamic recovery (A wave) Improvement in TDI BNP normalization Mass regression Chamber remodeling
Role of CMR
• More sensitive than echo• Explore tissue-dependent changes
through delayed enhancement Demonstrated in 70% patients (Maceira,
Pennell, et al. Circ 2005) associated with mass
• Small LV size + increased wall thickness does not necessarily = increased mass
CMR vs. echo
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
QuickTime™ and aYUV420 codec decompressor
are needed to see this picture.
CMR vs. echo
QuickTime™ and aMicrosoft Video 1 decompressorare needed to see this picture.
QuickTime™ and aYUV420 codec decompressor
are needed to see this picture.
Diffuse Delayed Enhancement
New echo approaches
• Strain imaging determines impaired longitudinal contraction (Koyama, Falk, et. al. Circ 2003) In absence of fractional shortening
abnormality Preceded CHF symptoms
• Utility of TDI with BNP to facilitate diagnosis in early disease
Applications of echo/CMR
• Early diagnosis • Predict outcomes with treatment• Monitor response to treatment